Higher Price Target for Ocera Therapeutics (NASDAQ: OCRX) as Hepatic Encephalopathy Treatment Study Moves Forward
An innovative potential treatment for hepatic encephalopathy created by Ocera Therapeutics, Inc. (NASDAQ: OCRX) is a unique product on an under-served market, and if clinical trials are successful, it could become a major source of success and profitability for the company, according to an Aegis Capital Corp. report (http://nnw.fm/cNkZ1) released on December 8. The report reiterates a ‘Buy’ rating for Ocera and recommends a higher stock price target of $8, compared to the $2.1 at the time of the analysis. The Aegis report was released a day after Ocera announced completion of enrollment in its phase 2B trials for lead…







